Background {#Sec1}
==========

Interferons (IFN) are known to have important direct anti-viral and anti-bacterial effects, as well as potent modulatory effects on the adaptive immune response via the induction of hundreds of IFN-stimulated genes (ISGs) \[[@CR1], [@CR2]\] The newest discovered class of IFN, the IFN lambda (IFNL) family, has four members: IFNL1--4 \[[@CR3]\]. The IFNL receptor consists of a heterodimer with an alpha subunit (IL28RA) and a beta subunit (IL10RB). IL10RB is ubiquitously expressed, whereas IL28RA expression is restricted and interestingly, it is highly expressed on lung epithelial cells \[[@CR4]\] and alveolar macrophages \[[@CR5]\]. When a virus is seen by the pattern recognition receptors which are found on macrophages and epithelial cells, IFNL gene expression is stimulated via various signalling pathways \[[@CR6]\]. This leads to increased circulating IFNL3 which interacts with the IFNL receptor expressed on lung, intestinal and liver cells, and via the JAK-STAT signalling cascade induces interferon stimulated genes which in turn influence viral replication \[[@CR6]\]. A series of single nucleotide polymorphisms (SNPs) in the IFNL3/4 gene region have been described \[[@CR7]--[@CR9]\] and associated with variable IFNL3/4 gene expression \[[@CR10]--[@CR13]\]. The variability of IFNL3 during viral or bacterial infections may lead to significant differences in the subsequent immune response and thus variable clinical outcomes \[[@CR3]\].

IFNL3 has immune-modulatory and anti-tumorigenic effects and is induced by viral infections \[[@CR6], [@CR14]\]. Viral infections play an important role in the exacerbation of asthma \[[@CR15]--[@CR17]\] and COPD \[[@CR18]--[@CR20]\]. Reduced interferon activity during a respiratory syncytial virus infection has been linked to the later development of asthma in children \[[@CR20], [@CR21]\]. The mechanism of virus-induced exacerbations of COPD is not well-defined. Recently, the role of IFNLs in the exacerbation of asthma has been explored \[[@CR22]--[@CR24]\]. However, no data are available regarding the effect of IFNL3 or its polymorphisms on the exacerbation and further clinical outcomes of COPD. COPD patients exposed to rhinovirus consistently showed a trend towards less IFNL expression in bronchoalveolar lavage fluid \[[@CR25]\] and in animal models it has been shown that IFNL plays a role in viral (influenza A, coronavirus and rotavirus) modulation \[[@CR6]\].

We hypothesize, that in patients with COPD, SNPs in the IFNL3/4 gene will impact clinical outcomes such as exacerbation and that they might be associated with circulating markers of inflammation and tissue remodelling. Therefore, we aimed to explore the IFNL3/4 polymorphisms (rs8099917 and rs12979860) and circulating IFNL3 in association with the occurrence of exacerbation of COPD and all-cause mortality in a multinational, multicenter, prospective, longitudinal, observational cohort study of patients with clinically stable and exacerbated COPD.

Methods {#Sec2}
=======

Study overview {#Sec3}
--------------

Patients in stable state COPD with GOLD II to IV were enrolled for an observational prospective trial (PROMISE-COPD; [www.controlled-trials.com](http://www.controlled-trials.com) identifier ISRCTN99586989). The study details have been published previously \[[@CR26]\]. For the current nested biomarker study, 638 patients were consecutively recruited and followed at 11 European hospital pneumology departments from November 2008 to October 2011 (Fig. [1](#Fig1){ref-type="fig"}). Details of inclusion and exclusion criteria were previously published \[[@CR27]\]. We analysed data from 528 patients, who completed the first 6 month-follow-up of the study and for whom serum samples from visit 1 were available. We used serum samples at the stable phase and during the first episode of exacerbation of COPD.Fig. 1Flow chart of the patient cohort selection criteria

For each patient, a physical examination was performed, vital signs were registered, and a detailed history obtained. Spirometry and 6-min walk tests (6MWTs) were performed following American Thoracic Society guidelines \[[@CR24], [@CR25]\]. One- and two-year follow-up in a stable phase, including a series of outcome markers were determined as previously published \[[@CR26]\]. Additionally, patients treated for infection-triggered exacerbation of COPD had a scheduled follow-up four weeks post-exacerbation onset. Acute exacerbations were defined as an acute sustained worsening of dyspnoea, cough and/or sputum beyond normal day-to-day variations in a patient with underlying COPD; severe exacerbations were defined as an exacerbation requiring hospitalisation \[[@CR28]\]. A total of 30 age and gender unmatched healthy controls were included in the study.

Ethics {#Sec4}
------

The study was an observational study without specific intervention. The IFNL3 genotypes and serum levels were retrospectively determined and had no impact on the treatment decisions. The study was approved by the respective participating local IRBs in all centers (Ethikkommission beider Basel EKBB/295707, Medical Ethical Committee Amphia Ziekenhuis 958, Medical Ethical Committee North Holland M08--016, Klinicki Centar Srbije Eticki Odbor, Clinical Research Ethics Committee Germans Trias I Pujol Hospital, Medizinische Hochschule Hannover Ethikkommission 5071, Ethics committee of the Hospital Clinic of Barcelona, Ethics committee of the Policlinico of Milan, Ethics committee in Greece). All patients provided a written informed consent.

IFNL3 ELISA assay {#Sec5}
-----------------

IFNL3 serum levels were determined in the stable phase and during exacerbation of COPD. A commercially available sandwich immunoassay ELISA kit that showed no cross-reactivity with IFNL2 (IL28A) or IFNL4 (IL29; Human IL-28B/IFN-lambda 3 DuoSet ELISA, DY5259, R&D Systems Minneapolis, MN, USA) was used, according to the manufacturer's instructions. The IFNL3 assay had a linear range of detection from 31.20--2000 pg/ml.

IFNL genotyping {#Sec6}
---------------

Two common SNPs, rs8099917 and rs12979860, in the IFNL3/L4 gene regions were determined as previously described \[[@CR11]\]. The distribution of minor and major allele genotypes is comparable to previous publications in European populations \[[@CR29], [@CR30]\].

Collagen markers {#Sec7}
----------------

As previously described \[[@CR31]\], serum levels of fragments of collagen type III (C3M), fragments of collagen type VI (C6M), pro-form of collagen type III (Pro-C3) and pro-form of collagen type VI (Pro-C6) were measured with Nordic Bioscience assays according to the manufacturer's instructions.

Inflammatory markers {#Sec8}
--------------------

Procalcitonin, Copeptin, pro-adrenomedullin (ADM), and atrial natriuretic polypeptide (ANP) were measured as previously described \[[@CR32]\].

Statistics {#Sec9}
----------

Differences in dichotomous variables were evaluated using the Chi-square test or Fischer's exact test, as appropriate. Normally distributed parameters were analyzed using the Student's t-test for equality of means. All other continuously non-normally distributed parameters were evaluated using the non-parametric Mann-Whitney U test or Kruskal-Wallis test, as appropriate. If the IFNL3 was below the detection level, the sample was assigned the value 31.20 pg/ml which is the lowest detectable value with the assay used in this study. Kaplan Meier curves were created to determine survival within 2 years and overall survival, occurrence of exacerbation and occurrence of severe exacerbation. The log-rank test was used to compare differences between survival curves. The Statistical Package for Social Sciences Program (SSPS Inc., version 22 for Windows) was used. All tests are two-tailed; a *p*-value of \< 0.05 was considered significant. Results are expressed as mean (standard deviation) or median (interquartile range), unless otherwise stated.

Results {#Sec10}
=======

Five hundred twenty eight patients were included in this nested study (Fig. [1](#Fig1){ref-type="fig"}). The majority of the patients were male (71%) and the average age was 66.9 years (Table [1](#Tab1){ref-type="table"}). 70% of the patients were past smokers and 50% of the patients were classified as GOLD II.Table 1Baseline characteristics of patients included in the studyMean (SD), *n* (%)Gender: Male377 (71)Age, years66.9 (9.3)Current smoker, n (%)157 (30)BMI (kg/m2)26.00 (5.13)Unadjusted Charlson Score (*n* = 528)1.82 (1--16)BODE index (median; IQR)3 (1--4)6MWT (m)380.61 (104.69)Exacerbation rate2.05 (0--15)Severe exacerbation rate0.39 (0--8)Lung function (post-brd) FEV~1~, in L1.40 (0.71) FVC, in L2.81 (0.89) FEV~1~/FVC%47.87 (13.97) FEV~1~, % predicted49.89 (16.8) FVC, % predicted80.70 (21.21)Collagen markers \[ng/ml\] C3M30.54 (12.61) C6M15.25 (8.62) Pro-C313.29 (10.03) Pro-C68.76 (4.31) EL-NE7.78 (6.78)GOLD Grade^a^ GOLD II262 (50) GOLD III180 (35) GOLD IV80 (15)rs8099917 genotypes TT339 (65) GG26 (5) TG155 (30)rs12979860 genotypes CC76 (30) TT45 (18) TC131 (52)MMRC score (median; IQR)2 (1--2)Inflammation markers at baseline Copeptin, pMol/L12.57 (16.66) Adrenomedullin, nMol/L0.69 (0.38) Atrial Natriuretic Peptide, pMol/L113.67 (101.03) Procalcitonin, μg/l0.09 (0.14)SF-36 Physical function51.54 (25.94) Role physical51.05 (43.48) Role emotional66.26 (43.52) Social Functioning69.49 (28.56) Mental Health64.89 (20.07) Body Pain74.19 (27.94) Vitality51.79 (21.00) General Health47.88 (22.90)SGRQ Symptoms score49.30 (22.65) Activity score57.22 (22.90) Impacts score32.11 (18.66) Total score42.39 (18.11)Continuous data are shown as mean (SD) or median (interquartile range) and categorical variables as No. (%). BMI = body mass index; brd = bronchodilator; BODE = BMI, airflow obstruction, dyspnea and exercise capacity; 6MWD = 6-min walk distance; C3M = fragments of collagen type III; C6M = fragments of collagen type VI; Pro-C3 = pro-forms of collagen type III; Pro-C6 = pro-forms of collagen type VI; EL-NE = neutrophil elastase-generated fragments of elastin; GOLD = Gold Initiative for Chronic Obstructive Lung Disease; MMRC = modified Medical Research Council; SF-36 = 36-item Short-Form Health Survey; SGRQ = St. George's Respiratory Questionnaire^a^GOLD grades are based on FEV1% predicted: 50% ≤ II ≤ 80%; 30% ≤ III ≤ 50%; and IV ≤ 30%

IFNL3 genotyping {#Sec11}
----------------

The distribution of both rs8099917 and rs12979860 SNPs adhered to the Hardy Weinberg Equilibrium with the χ2 test for deviation equalling 2.21 for rs8099917 and 0.781 for rs12979860. Both values were less than 3.84 which represents the 5% significance level for 1 degree of freedom and therefore the null hypothesis that the population is in the Hardy-Weinberg frequencies is not rejected \[[@CR33]\]. The most common genotype rs8099917 TT (65%) was followed by TG (30%) and GG (5%; Table [1](#Tab1){ref-type="table"}).

Patients with the rs8099917 GG genotype had a significantly shorter time to severe exacerbation than patients with the TT or TG genotype (Fig. [2](#Fig2){ref-type="fig"}; *p* = 0.037). Significantly more severe exacerbations occurred in patients with rs8099917 GG genotype compared to patients with rs8099917 TT or rs8099917 TG genotype (42 vs 23%, respectively; chi-squared *p* = 0.032). The rs8099917 genotypes had no significant effect on mortality (*p* = 0.726). There was a significant association between MMRC and the rs8099917 GG genotype with 42% (11/26) of patients with the GG genotype having an MMRC more than the median compared to 22% (107/479) of patients with rs8099917 TT or rs8099917 TG genotype (Table [2](#Tab2){ref-type="table"}; chi-squared, *p* = 0.030). Although there was no difference in the unadjusted Charlson score (*p* = 0.705), suggesting a similar distribution of comorbidities and life expectancy between the groups, five times the number of patients with rs8099917 GG genotype had been diagnosed with a malignancy at the start of the study compared to patients with rs8099917 TT or rs8099917 TG genotype (chi-squared, *p* = 0.014). The association between rs8099917 GG genotype and having a malignancy remained after adjusting for age and smoking (OR = 6.726, *p* = 0.003). Mann-Whitney-U-Test showed a significant difference in C6M between rs8099917 GG genotype and rs8099917 TT/TG genotype (Table [2](#Tab2){ref-type="table"}).Fig. 2Kaplan Meier curve showing the significant effect of the rs8099917 GG genotype on time to severe exacerbation; *p* = 0.037. GG *p* = 26, 11 events; TT *n =* 335, events = 73; TG *n* = 154, events = 39Table 2A comparison of the patient baseline characteristics according to their rs8099917 genotypeGG (median, IQR)TT/TG (median, IQR)*p*-valueGender: Male (n,%)16 (61.5)355 (71.9)0.269Age, years70.50 (14.50)67.00 (13)0.139Current smoker (n, %)4 (15.4)149 (30.3)0.125PY, months40.00 (36.75)45.00 (35)0.261BMI, kg/m227.29 (7.83)25.86 (6.14)0.339Unadjusted Charlson Score1.00 (2.00)1.00 (1.00)0.3056MWT, m375 (161.25)395 (120)0.362Exacerbation rate (number of exacerbations/year)2.00 (3.00)1.00 (3.00)0.935Severe exacerbation rate (number of severe exacerbations/year)0.58 (0--3)0.37 (0--8)*0.033*Lung function (post-brd) FEV~1~, in L1.31 (0.8)1.32 (0.74)0.749 FVC, in L2.53 (1.95)2.69 (1.07)0.688 FEV~1~/FVC%49.38 (27.47)47.00 (22.91)0.723 FEV~1~, % predicted56.50 (28.17)49.50 (25.15)0.314 FVC, % predicted82.40 (42.75)80.00 (26.22)0.349BODE index0.659  ≤ median of 315 (62.5)302 (67.3)  \> median of 39 (37.5)147 (32.7)Collagen markers \[ng/ml\] C3M25.3 (14.5)28.6 (11.6)0.302 C6M11.0 (9.7)13.3 (8.1)*0.032* Pro-C312.1 (6.1)10.8 (5.6)0.684 Pro-C68.1 (3.7)8.0 (0.535)1.000GOLD Grade^a^ (n,%)0.699 GOLD II15 (57.7)242 (49.6) GOLD III8 (30.8)169 (34.6) GOLD IV3 (11.5)77 (15.8)MMRC Test (n,%)*0.030*  ≤ median of 215 (57.7)372 (77.7)  \> median of 211 (42.3)107 (22.3)Inflammation markers Copeptin, pMol/l8.24 (10.45)8.57 (12.53)0.465 Adrenomedullin, nMol/l0.60 (0.28)0.60 (0.3)0.929 ANP, pMol/l91.38 (52.43)83.47 (83.18)0.408 Procalcitonin, μg/l0.08 (0.03)0.08 (0.03)0.862SF-36 Physical function45 (47.5)50 (45)0.346 Role physical50 (100)50 (100)0.742 Role emotional100 (75)100 (100)0.518 Social Functioning75 (65.6)75 (50)0.852 Mental Health67.50 (36.25)65 (27.50)0.780 Body Pain80 (58)80 (48)0.720 Vitality46.88 (32.81)50 (31.25)0.403 General Health37.50 (42.5)50 (36.69)0.570SGRQ Symptoms score46.60 (26.87)49.72 (34.44)0.356 Activity score66.19 (31.99)54.43 (31.81)0.607 Impact score29.16 (25.68)29.39 (26.46)0.802 Total score44.15 (31.27)39.03 (27.54)0.892Continuous data are shown as median (interquartile range) and categorical variables as No. (%). Italicized *p*-values are statistically significant, ie. *p* \< 0.05. *BMI* body mass index, *brd* bronchodilator, *BODE* BMI, airflow obstruction, dyspnea and exercise capacity; *6MWD* 6-min walk distance, *C3M* fragments of collagen type III, *C6M* fragments of collagen type VI, *Pro-C3* pro-forms of collagen type III, *Pro-C6* pro-forms of collagen type VI, *GOLD* Gold Initiative for Chronic Obstructive Lung Disease, *MMRC* modified Medical Research Council, *ANP* Atrial Natriuretic Peptide, *SF-36* 36-item Short-Form Health Survey, *SGRQ* St. George's Respiratory Questionnaire^a^GOLD grades are based on FEV1% predicted: 50% ≤ II ≤ 80%; 30% ≤ III ≤ 50%; and IV ≤ 30%

The rs12979860 genotypes had no effect on mortality (*p* = 0.703), exacerbation rate (*p* = 0.946) or time to exacerbation (*p* = 0.324). The rs12979860 CC genotype was associated with BODE index with 46% (30/65) of the patients with a BODE index more than the median compared to 36% (44/122) of patients with the rs12979860 TC and 20.5% (8/39) of patients with the rs12979860 TT genotype (*p* = 0.031).

Circulating IFNL3 in serum {#Sec12}
--------------------------

Circulating IFNL3 was detectable in 3.6% (19/528) of the COPD patients during stable phase and in 7.2% (32/446) of the COPD patients during the exacerbation phase whereas it was detectable in 80% (24/30) of the blood samples from healthy controls. The level of IFNL3 was higher in the controls compared to the COPD patients during stable phase, exacerbation phase and follow-up to the exacerbation (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Circulating IFNL3 during stable COPD, in healthy controls, during exacerbation and during follow up to exacerbation 4 weeks later

There was no association between the rs8099917 (chi-square test; *p* = 0.392) or rs12979860 genotypes (chi-square test; *p* = 0.733) and whether IFNL3 was detectable or not during the stable phase.

Circulating IFNL3 during stable COPD phase {#Sec13}
------------------------------------------

None of the patients with a GOLD IV classification had detectable circulating IFNL3 during stable phase. 3% (5/180) of the patients classified as GOLD III and 5% (14/262) of the patients classified as GOLD II had detectable circulating IFNL3 levels. GOLD II (31.2 pg/ml; Range = undetectable -- 661.83) and GOLD III (31.2 pg/ml; Range = undetectable -- 122.26) patients had similar levels of circulating IFNL3, which was less than in healthy controls (82.7 pg/ml; IQR = 81.9--83.4). Using a Mann-Whitney-U-test, patients with detectable circulating IFNL3 had significantly better post-bronchodilator FEV~1~%predicted than patients with undetectable IFNL3 (57.97 vs. 49.62; *p* = 0.035). We found a significant correlation between circulating IFNL3 and post bronchodilator FEV~1~%predicted (Spearman Rho = 0.098; *p* = 0.034). There was no significant difference in other variables, including quality of life, between patients with detectable circulating IFNL3 and patients with non-detectable circulating IFNL3.

Circulating IFNL3 and collagen biomarkers {#Sec14}
-----------------------------------------

There was a significant association between circulating IFNL3 and Pro-C3 (Linear regression, Beta = 0.099 95% CI 0.037--0.634; *p* = 0.028) but no association with C3M, C6Mor Pro-C6. Patients with detectable circulating IFNL3 had significantly more Pro-C3 than patients with undetectable levels of IFNL3 (Mann-Whitney U-Test, median 16.1 \[IQR = 8.0\] vs 10.7 \[IQR = 5.6\] ng/ml, respectively; *p* = 0.003). There was no significant difference in the other collagen biomarkers between the two groups of patients.

Discussion {#Sec15}
==========

Viral infections are thought to play a role in the exacerbation of COPD \[[@CR18], [@CR19]\]. IFNL3, a member of the interferon lambda family, has immune-modulatory and anti-tumorigenic effects and is induced by viral infections \[[@CR14]\]. This is the first study evaluating the association between IFNL circulating levels and its polymorphisms in patients with COPD.

The distribution of both rs8099917 and rs12979860 SNPs adhered to the Hardy Weinberg Equilibrium. Ethnic background strongly impacts SNP distribution, however, people with Caucasian ancestry (the main ethnic background of the present cohort) have a more balanced distribution of genetic polymorphisms \[[@CR9], [@CR34]\]. In our COPD cohort, the SNP rs8099917 GG genotype significantly influenced the severe exacerbation rate, and the time to severe exacerbation and it was associated with a higher MMRC score. Conversely, SNP rs12979860 had no effect on exacerbations or death. This is in line with what is known for hepatitis and diabetes, where the SNP rs8099917 GG genotype is considered to be the risk genotype and the SNP rs12979860 CC genotype the protective genotype \[[@CR35]--[@CR37]\]. The IFNL3 polymorphisms predict response to treatment in patients with hepatitis C \[[@CR27], [@CR30], [@CR31]\]. We found that the prevalence of malignancy was increased among patients with the rs8099917 GG genotype. This was also seen in patients with chronic hepatitis C, where more patients with the rs8099917 GG or non-TT genotype had hepatocellular carcinoma \[[@CR38]\]. In antiretroviral-treated HIV-infected patients, however, the SNP rs12979860 CC genotype was associated with higher mortality and thus it was not protective \[[@CR39]\]. In COPD patients, we found that the SNP rs12979860 CC genotype was associated with a higher BODE index, and thus possibly a higher risk of mortality, though the rs12979860 CC genotype did not associate with mortality directly in this study.

We found no association between the genotype and the circulating IFNL3 levels. In the literature, the association between genotype and circulating IFNL3 levels varies according to illness and group. Arpaci et al. \[[@CR40]\] found no association between genotype and circulating IFNL3 in patients with Hashimoto's Thyroiditis. Langhans et al. \[[@CR41]\] found that hepatitis C patients with the protective SNP rs12979860 CC genotype had more circulating IFNL3 compared to patients with the SNP rs12979860 TT genotype whereas Alborzi A., et al. \[[@CR42]\] found no association between circulating IFNL3 and genotype.

Less IFNL3 is secreted by primary cells from asthmatic patients compared to cells from healthy controls infected with a virus but the basal levels are similar between the two groups \[[@CR22]\]. Bullens et al. \[[@CR43]\] found increased basal IFNL3 mRNA in the sputum of asthmatic patients compared to controls. Thus far there is no literature regarding basal serum IFNL3 levels in asthma patients compared to controls. Circulating IFNL3 levels were similar between hepatitis C patients and healthy controls \[[@CR41]\] and Arpaci et al. \[[@CR40]\] found increased basal circulating IFNL3 in patients with Hashimoto's thyroiditis compared to healthy controls. In our cohort of COPD patients, basal circulating IFNL3 levels were significantly less compared to controls. The circulating IFNL3 levels increased during an exacerbation, as was also seen in vitro in the cells from asthmatic patients that were infected with virus \[[@CR22]\], and then returned to basal levels after the patient had recovered from the exacerbation. In COPD, the basal circulating IFNL3 levels were associated with the severity of airflow limitation. We hypothesise that the difference in circulating IFNL3 between healthy donors, GOLD II, GOLD III and GOLD IV patients may be due not only to the association between IFNL3 and FEV1, but also due to remodelling of the extracellular matrix in the lungs. This hypothesis is in part corroborated by the fact that there is a strong association between circulating IFNL3 and Pro-C3. Pro-C3 is the N-protease cleavage site of type III collagen and is a marker of tissue formation \[[@CR44]\]. Low levels of Pro-C3 is associated with worse lung function \[[@CR31], [@CR45]\] and with a shorter time to severe exacerbation \[[@CR31]\]. It is therefore possible that changes in the cell structure of the lung results in decreased secreted IFNL3 which causes an impaired immune response to infection. More exacerbations occur resulting in more remodelling of the cells and less IFNL3 secretion, both of which are associated with impaired lung function, and a vicious cycle is continued. It is also possible that the decreased circulating IFNL3 facilitates viral infection leading to less Pro-C3 which results in worse lung function and shorter time to exacerbation. We are unable to determine which element is the catalyst therefore further studies are required to explore the association between IFNL3 polymorphisms and the remodelling of the extra-cellular matrix in stable and exacerbated COPD.

We found no association between circulating IFNL3 levels and disease outcome as is also evident in patients with hepatitis C \[[@CR41]\].

The main limitation to this study is that there are no genotyping results for healthy controls and the SNP data was not validated in a separate cohort. We only investigated two SNPs, further studies are needed to investigate other SNPs related to IFNL3. In addition, the circulating IFNL3 was measured from unmatched blood donor samples. However, we found no association between circulating IFNL3 levels and gender or age, so the differences seen between the healthy controls and the COPD patients probably are not due to gender or age differences. The clinical value of IFNL3 alone or in combination with other biomarkers has to be assessed in conformational and randomized clinical trials.

Strengths of the study include the originality, longitudinal design assessing clinically relevant end-points and the fact that both genotypes and circulating IFNL3 were determined in a large multicentric cohort.

Conclusions {#Sec16}
===========

IFNL3 polymorphisms may play a role in disease activity and outcomes in COPD and circulating IFNL3 may be associated with disease severity and stability. Further investigations are required to determine the underlying mechanisms.
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